|
 PARIS (Reuters) - Novacyt, a healthcare company specializing in
clinical diagnostics, announced on Monday approval from the U.S.
Food & Drug Administration (FDA) regulator for its product aimed at
testing for coronavirus.
Novacyt said the FDA's approval meant that hospitals and
laboratories in the United States would be able to use the test for
clinical diagnosis of the coronavirus, and that the test was now
available for immediate distribution in the U.S. market.
[to top of second column] |
"The U.S. FDA EUA authorization is another important endorsement of the
performance and quality of our COVID-19 test and demonstrates once again
Novacyt's growing role in tackling this pandemic," said Novacyt CEO Graham
Mullis.
(Reporting by Sudip Kar-Gupta, editing by Louise Heavens)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
